(Reuters) – Nektar Therapeutics and Bristol Myers Squibb said on Thursday they have jointly decided to end the global clinical development program for their cancer drug bempegaldesleukin in combination with Opdivo.
(Reporting by Leroy Leo in Bengaluru; Editing by Maju Samuel)
